Related Experiment Videos
Chemotherapy-induced scleroderma: a pleiomorphic syndrome.
D T Alexandrescu1, N S Bhagwati, P H Wiernik
1Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA. mddoru@hotmail.com
Clinical and Experimental Dermatology
|February 24, 2005
Summary
Chemotherapy drugs like doxorubicin and cyclophosphamide can cause diffuse scleroderma, a skin condition. This case report details its presentation and course in a breast cancer patient.
Area of Science:
- Oncology
- Dermatology
- Pathology
Background:
- Scleroderma-like skin conditions have been linked to taxane chemotherapy.
- This study investigates a rare case of diffuse scleroderma in a breast cancer patient.
Observation:
- The patient developed diffuse scleroderma during doxorubicin and cyclophosphamide treatment.
- Skin and histological findings mimicked classical scleroderma.
- Skin involvement reached 80% of body area and persisted despite cancer progression.
Findings:
- The scleroderma's presentation and progression suggest a direct link to specific chemotherapeutic agents, rather than a paraneoplastic cause.
- Analysis of similar cases helps define the characteristics and clinical course of this phenomenon.
Implications:
- This highlights a potential adverse effect of certain chemotherapy regimens.
- Understanding this association is crucial for patient monitoring and management in oncology.
- Further research may elucidate the precise mechanisms driving chemotherapy-induced scleroderma.